Stifel on Compass Therapeutics (CMPX): 'Path Forward Complicated by FDA’s “Imply-No-Harm” Mandate'
Tweet Send to a Friend
Stifel analyst Stephen Willey reiterated a Buy rating and $12.00 price target on Compass Therapeutics (NASDAQ: CMPX).The analysdt comments "Secondary ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
